Dr. Thomas Detweiler, M.D

NPI: 1659310704
Total Payments
$581.90
2018 Payments
$202.95
Companies
6
Transactions
8

Payment Breakdown by Category

Food & Beverage$356.90 (61.3%)
Consulting$225.00 (38.7%)

Payments by Nature

Nature of Payment Amount Transactions Share
Food and Beverage $356.90 7 61.3%
Consulting Fee $225.00 1 38.7%

Top Paying Companies

Company Total Records Latest Year
GlaxoSmithKline, LLC. $225.00 1 $0 (2017)
Boehringer Ingelheim Pharmaceuticals, Inc. $112.56 2 $0 (2018)
Regeneron Healthcare Solutions, Inc. $77.35 1 $0 (2017)
Novartis Pharmaceuticals Corporation $76.60 1 $0 (2017)
Medtronic USA, Inc. $73.76 2 $0 (2018)
Takeda Pharmaceuticals U.S.A., Inc. $16.63 1 $0 (2018)

Payment History by Year

Year Amount Transactions Top Company
2018 $202.95 5 Boehringer Ingelheim Pharmaceuticals, Inc. ($112.56)
2017 $378.95 3 GlaxoSmithKline, LLC. ($225.00)

All Payment Transactions

8 individual payment records from CMS Open Payments

Date Company Product Nature Form Amount Type
10/23/2018 Boehringer Ingelheim Pharmaceuticals, Inc. Food and Beverage In-kind items and services $100.72 General
10/23/2018 Boehringer Ingelheim Pharmaceuticals, Inc. OFEV (Drug) Food and Beverage In-kind items and services $11.84 General
Category: ONCOLOGY
08/09/2018 Takeda Pharmaceuticals U.S.A., Inc. Trintellix (Drug) Food and Beverage In-kind items and services $16.63 General
Category: Central Nervous System (CNS)
02/02/2018 Medtronic USA, Inc. MazorX - Renaissance (Device) Food and Beverage In-kind items and services $36.62 General
Category: Enabling
02/01/2018 Medtronic USA, Inc. MazorX - Renaissance (Device) Food and Beverage In-kind items and services $37.14 General
Category: Enabling
11/20/2017 Novartis Pharmaceuticals Corporation ENTRESTO (Drug) Food and Beverage In-kind items and services $76.60 General
Category: CARDIOVASCULAR
11/09/2017 Regeneron Healthcare Solutions, Inc. DUPIXENT DUPILUMAB INJECTION (Biological) Food and Beverage In-kind items and services $77.35 General
Category: INFLAMMATION AND IMMUNOLOGY
04/28/2017 GlaxoSmithKline, LLC. BREO (Drug) Consulting Fee Cash or cash equivalent $225.00 General
Category: RESPIRATORY

About Dr. Thomas Detweiler, M.D

Dr. Thomas Detweiler, M.D is a Internal Medicine healthcare provider based in Medford, Oregon. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/05/2006. The National Provider Identifier (NPI) number assigned to this provider is 1659310704.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Thomas Detweiler, M.D has received a total of $581.90 in payments from pharmaceutical and medical device companies, with $202.95 received in 2018. These payments were reported across 8 transactions from 6 companies. The most common payment nature is "Food and Beverage" ($356.90).

Practice Information

  • Specialty Internal Medicine
  • Other Specialties Internal Medicine
  • Location Medford, OR
  • Active Since 06/05/2006
  • Last Updated 12/20/2019
  • Taxonomy Code 207R00000X
  • Entity Type Individual
  • NPI Number 1659310704

Products in Payments

  • BREO (Drug) $225.00
  • DUPIXENT DUPILUMAB INJECTION (Biological) $77.35
  • ENTRESTO (Drug) $76.60
  • MazorX - Renaissance (Device) $73.76
  • Trintellix (Drug) $16.63
  • OFEV (Drug) $11.84

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Internal Medicine Doctors in Medford